Overview

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection

Status:
Not yet recruiting
Trial end date:
2023-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC